Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
Stopped early · Phase 1
Conditions studied: Colon Cancer, Rectal Cancer
In brief
RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving lenalidomide together with cetuximab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when given together with cetuximab in treating patients with metastatic colorectal cancer.
Key facts
- Study ID
- NCT01126450
- Run by
- Case Comprehensive Cancer Center
- People needed
- 3
- Starts
- 2009-10-01
- Expected to finish
- 2010-12-01
- Last updated by the study team
- 2012-03-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.